You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The German molecular diagnostics firm recently completed a capital increase with subscription rights for existing shareholders, grossing €22.3 million.
Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.
The company attributed the growth to increasing global demand for breast cancer testing, and growing demand and reimbursement for its prostate test.
Wired reports that increased diversity is needed in the Breakthrough Prizes.
Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.
Given that genetic susceptibility to schizophrenia is highly polygenic, the researchers found that the risk scores had some utility as prognostic biomarkers.
Separate research groups have examined the genomes of modern and ancient Mongolian populations to study their ancestry, finding a relationship to Native Americans.
Researchers identified gene family expansions and other parasitic adaptations using genome sequences for 81 roundworms or flatworms.
The Wellcome Trust and the Bill & Melinda Gates Foundation have joined the open-access initiative Plan S, according to ScienceInsider.
Last week, GenomeWeb's readers were most interested in Illumina's plans to acquire Pacific Biosciences for approximately $1.2 billion in cash.
The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine.
The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.
The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.
In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.